Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

José L. Blanco; Julio S G Montaner; Vincent C. Marconi; Maria M. Santoro; Ariel E. Campos-Loza; Robert W. Shafer; Michael D. Miller; Roger Paredes; Richard Harrigan; Mihn L. Nguyen; Carlo F. Perno; Lucero A. Gonzalez-Hernandez; José M. Gatell

doi:10.1097/QAD.0000000000000424

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

José L. Blanco, Julio S G Montaner, Vincent C. Marconi, Maria M. Santoro, Ariel E. Campos-Loza, Robert W. Shafer, Michael D. Miller, Roger Paredes, Richard Harrigan, Mihn L. Nguyen, Carlo F. Perno, Lucero A. Gonzalez-Hernandez, José M. Gatell

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

Original language	English
Pages (from-to)	2531-2539
Number of pages	9
Journal	AIDS (London, England)
Volume	28
Issue number	17
DOIs	https://doi.org/10.1097/QAD.0000000000000424
Publication status	Published - 2014

Keywords

Antiretroviral treatment
Atripla
HIV-1 resistance
Single-tablet regimen

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases
Medicine(all)

Access to Document

10.1097/QAD.0000000000000424

Fingerprint

Dive into the research topics of 'Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy'. Together they form a unique fingerprint.

Cite this

Blanco, J. L., Montaner, J. S. G., Marconi, V. C., Santoro, M. M., Campos-Loza, A. E., Shafer, R. W., Miller, M. D., Paredes, R., Harrigan, R., Nguyen, M. L., Perno, C. F., Gonzalez-Hernandez, L. A., & Gatell, J. M. (2014). Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. AIDS (London, England), 28(17), 2531-2539. https://doi.org/10.1097/QAD.0000000000000424

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. / Blanco, José L.; Montaner, Julio S G; Marconi, Vincent C. et al.

In: AIDS (London, England), Vol. 28, No. 17, 2014, p. 2531-2539.

Research output: Contribution to journal › Article › peer-review

Blanco, JL, Montaner, JSG, Marconi, VC, Santoro, MM, Campos-Loza, AE, Shafer, RW, Miller, MD, Paredes, R, Harrigan, R, Nguyen, ML, Perno, CF, Gonzalez-Hernandez, LA & Gatell, JM 2014, 'Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy', AIDS (London, England), vol. 28, no. 17, pp. 2531-2539. https://doi.org/10.1097/QAD.0000000000000424

@article{e2d8eebf990d43ec9215052886e1571f,

title = "Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy",

abstract = "Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.",

keywords = "Antiretroviral treatment, Atripla, HIV-1 resistance, Single-tablet regimen",

author = "Blanco, {Jos{\'e} L.} and Montaner, {Julio S G} and Marconi, {Vincent C.} and Santoro, {Maria M.} and Campos-Loza, {Ariel E.} and Shafer, {Robert W.} and Miller, {Michael D.} and Roger Paredes and Richard Harrigan and Nguyen, {Mihn L.} and Perno, {Carlo F.} and Gonzalez-Hernandez, {Lucero A.} and Gatell, {Jos{\'e} M.}",

year = "2014",

doi = "10.1097/QAD.0000000000000424",

language = "English",

volume = "28",

pages = "2531--2539",

journal = "AIDS",

issn = "0269-9370",

publisher = "NLM (Medline)",

number = "17",

}

TY - JOUR

T1 - Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

AU - Blanco, José L.

AU - Montaner, Julio S G

AU - Marconi, Vincent C.

AU - Santoro, Maria M.

AU - Campos-Loza, Ariel E.

AU - Shafer, Robert W.

AU - Miller, Michael D.

AU - Paredes, Roger

AU - Harrigan, Richard

AU - Nguyen, Mihn L.

AU - Perno, Carlo F.

AU - Gonzalez-Hernandez, Lucero A.

AU - Gatell, José M.

PY - 2014

Y1 - 2014

N2 - Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

AB - Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

KW - Antiretroviral treatment

KW - Atripla

KW - HIV-1 resistance

KW - Single-tablet regimen

UR - http://www.scopus.com/inward/record.url?scp=84927774765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927774765&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000424

DO - 10.1097/QAD.0000000000000424

M3 - Article

C2 - 25574957

AN - SCOPUS:84927774765

VL - 28

SP - 2531

EP - 2539

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 17

ER -

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this